Marie Thibault
Stock Analyst at BTIG
(4.21)
# 456
Out of 4,970 analysts
77
Total ratings
57.75%
Success rate
13.7%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Downgrades: Neutral | n/a | $2.74 | - | 2 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $148 → $145 | $132.81 | +9.18% | 12 | Jul 18, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $35.66 | +45.82% | 7 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $120 → $124 | $107.29 | +15.57% | 10 | Apr 23, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $14.49 | +79.43% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $346.47 | -22.07% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $143.01 | +18.87% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $38.71 | +67.92% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $54.08 | +107.10% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $80.76 | +48.59% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.17 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.27 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $11.10 | +80.18% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $182.17 | -23.15% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.51 | +363.58% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.31 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.45 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $230.50 | -97.40% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.74
Upside: -
Abbott Laboratories
Jul 18, 2025
Maintains: Buy
Price Target: $148 → $145
Current: $132.81
Upside: +9.18%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $35.66
Upside: +45.82%
Boston Scientific
Apr 23, 2025
Maintains: Buy
Price Target: $120 → $124
Current: $107.29
Upside: +15.57%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $14.49
Upside: +79.43%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $346.47
Upside: -22.07%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $143.01
Upside: +18.87%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $38.71
Upside: +67.92%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $54.08
Upside: +107.10%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $80.76
Upside: +48.59%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.27
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $11.10
Upside: +80.18%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $182.17
Upside: -23.15%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.51
Upside: +363.58%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.31
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.45
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $230.50
Upside: -97.40%